Elena Santagostino
Sobi AB · Swedish Orphan Biovitrum · Centro Emofilia e Trombosi Angela Bianchi Bonomi, IRCCS Fondazione Ospedale Maggiore Policlinico
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Elena Santagostino as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 10:09 UTC. Open this list on ClinicalTrials.gov
- Ph1NCT06579144 · Pharmacokinetic Comparison of Efanesoctocog Alfa vs Other EHL-rFVIII Products in Participants With Severe Haemophilia ASwedish Orphan Biovitrum · completed · Hemophilia A · study director
- N/ANCT04133883 · Impact on French Physician's Haemophilia Treatment Management Decision Based on Systematic Joint ExaminationSwedish Orphan Biovitrum · completed · Hemophilia A · study director
- N/ANCT03901755 · An International Study to Evaluate the Real-world Effectiveness and Usage of Alprolix in Patients With Haemophilia BSwedish Orphan Biovitrum · completed · Hemophilia B · study director
- N/ANCT03655340 · A Study to Evaluate the Real-world Effectiveness and Usage of Alprolix in Patients With Haemophilia B in FranceSwedish Orphan Biovitrum · completed · Haemophilia B · study director
- Ph4NCT02479087 · Safety/Efficacy Study to Assess Whether FVIII/VWF Concentrate Can Induce Immune Tolerance in Haemophilia A PatientsFondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico · unknown · Hemophilia A · study director
- N/ANCT01652027 · Hemophilia Inhibitor Previously Untreated Patient StudyThe University of Texas Health Science Center, Houston · completed · Hemophilia A · principal investigator
- N/ANCT01505946 · Thrombin Generation Assay (TGA) as Predictive Test for Haemostatic. Effectiveness of FVIII Concentrates in Haemophiliac A With InhibitorsGrifols Italia S.p.A · unknown · Severe Hemophilia A With Inhibitor · principal investigator
- Ph2NCT01105546 · rFVIIa Prophylaxis in Children With Hemophilia A and InhibitorsFondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico · unknown · Hemophilia A With Inhibitors · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 10:09 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 10:09 UTC. The ranking covers the 200 most relevant of 63 PubMed records, and a shared surname and initials can bring in a namesake. All 63 on PubMed
- Emicizumab Prophylaxis in Hemophilia A with Inhibitors.N Engl J Med · 2017913 citationsRCR 38.0
- 394 citationsRCR 16.7
- 183 citationsRCR 7.0
- A prospective randomized trial of high and standard dosages of recombinant factor VIIa for treatment of hemarthroses in hemophiliacs with inhibitors.J Thromb Haemost · 2006141 citationsRCR 4.9
- Pharmacokinetics of activated recombinant coagulation factor VII (NovoSeven) in children vs. adults with haemophilia A.Haemophilia · 2004119 citationsRCR 4.0
- Home treatment with recombinant activated factor VII in patients with factor VIII inhibitors: the advantages of early intervention.Br J Haematol · 1999103 citationsRCR 4.0
- Clinical evaluation of glycoPEGylated recombinant FVIII: Efficacy and safety in severe haemophilia A.Thromb Haemost · 201796 citationsRCR 4.7
- Relationship between factor VII activity and clinical efficacy of recombinant factor VIIa given by continuous infusion to patients with factor VIII inhibitors.Thromb Haemost · 200188 citationsRCR 3.3
- The effect of emicizumab prophylaxis on health-related outcomes in persons with haemophilia A with inhibitors: HAVEN 1 Study.Haemophilia · 201972 citationsRCR 4.7
- 70 citationsRCR 3.1